Pyrimidinedione derivatives

1. Novel pyrimidinedione derivatives of the formula (I)

their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their solvates, their pharmaceutically acceptable salts and their pharmaceutically acceptable compositions, wherein X and Y may be same or different and independently represent oxygen, sulfur or NR, wherein R represents hydrogen, hydroxyl, acyl, alkyl, alkoxy, aryl, amino, hydroxylamino, alkylamino, arylamino, acylamino, alkoxyamino group; the rings represented by A and B are selected from aryl or heteroaryl; R 1 and R 3 may be same or different and independently represent SR 7 , wherein R 7 represents alkyl or aryl, or S(O) p R 8 , wherein R 8 represents alkyl, amino or aryl group and p represents an integer of 1 or 2; R 2 and R 4 may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, alkylsulfonyl, alkylsulfinyl, alkylsulfanyl, sulfamoyl, alkoxyalkyl groups or carboxylic acids or its derivatives; R 5 and R 6 may be same or different and independently represent hydrogen, halogen, hydroxyl, formyl, cyano, nitro, nitroso, amino, alkyl, acyl, monoalkylamino, dialkylamino, arylamino, acylamino, alkoxyalkyl or COR 9 , wherein R 9 represents hydroxyl, amino, halogen, alkoxy, aryloxy, monoalkylamino, dialkylamino, arylamino, groups; m is an integer and is in the range of 0 to 2; n is an integer and is in the range of 0 to 2.

2. Novel pyrimidinedione derivatives as claimed in claim 1 , wherein the ring systems represented by A and B are selected from phenyl, naphthyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyrimidinyl, benzopyranyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzopyrolyl, benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, benzothienyl, benzofuranyl or indolyl.

3. Novel pyrimidinedione derivatives as claimed in claim 1 , which are selected from:

1-(4-Methylsulfanyl-phenyl)-6-phenyl-pyrimidin-2,4-(1H)-dione;

6-(4-Methylphenyl)-1-(4-methylsulfanyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Ethylphenyl)-1-(4-methylsulfanyl-phenyl)-pyrimidin-2,4-(1H)-dione;

1-(4-Methylphenyl)-6-(4-methylsulfanyl-phenyl)-pyrimidin-2,4-(1H)-dione;

1-(4-Bromophenyl)-6-(4-methylsulfanyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Chlorophenyl)-1-(4-methylsulfanyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Chloro-3-methylphenyl)-1-(4-methylsulfanyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(3-Chloro-4-methylphenyl)-1-(4-methylsulfanyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Fluoro-3-methylphenyl)-1-(4-methylsulfanyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Fluorophenyl)-1-(4-methylsulfanyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Methylsulfanyl-phenyl)-1-phenyl-pyrimidin-2,4-(1H)-dione;

6-(4-Methylphenyl)-1-(3-chloro-4-methylsulfonyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Methoxy-3-methylphenyl)-1-(4-methylsulfonyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Methylphenyl)-1-(4-methylsulfonyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Ethylphenyl)-1-(4-methylsulfonyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Chlorophenyl)-1-(4-methylsulfonyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Chloro-3-methylphenyl)-1-(4-methylsulfonyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Chlorophenyl)-1-(3-methoxy-4-methylsulfonyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(3-Chloro-4-methylphenyl)-1-(4-methylsulfonyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Fluorophenyl)-1-(4-methylsulfonyl-phenyl)-pyrimidin-2,4-(1H)-dione;

1-(4-Methylsulfonyl-phenyl)-6-phenyl-pyrimidin-2,4-(1H)-dione;

1-(4-Methylsulfanyl-phenyl)-6-(pyridin-2-yl)-pyrimidin-2,4-(1H)-dione;

6-(4-Methylpyridin-2-yl)-1-(4-methylsulfanyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Chloropyridin-2-yl)-1-(4-methylsulfanyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Methylsulfanyl-phenyl)-1-(pyridin-2-yl)-pyrimidin-2,4-(1H)-dione;

1-(4-Methylsulfonyl-phenyl)-6-(pyridin-2-yl)-pyrimidin-2,4-(1H)-dione;

6-(4-Methylpyridin-2-yl)-1-(4-methylsulfonyl-phenyl)-pyrimidin-2,4-(1H)-dione;

6-(4-Chloropyridin-2-yl)-1-(4-methylsulfonyl-phenyl)-pyrimidin-2,4-(1H)-dione;

4-(2,4-Dioxo-6-(4-methylphenyl)-3,4-dihydro-2H-pyrimidin-1-yl)-benzenesulfonamide;

4-(2,4-Dioxo-6-phenyl-3,4-dihydro-2H-pyrimidin-1-yl)-benzenesulfonamide;

4-[6-(4-Bromo-phenyl)-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl]-benzenesulfonamide;

4-(2,6-Dioxo-3-phenyl-1,2,3,6-tetrahydro-pyrimidin-4-yl)-benzenesulfonamide;

4-(2,6-Dioxo-3-(4-methylsulfanyl-phenyl)-1,2,3,6-tetrahydro-pyrimidin-4-yl)-benzenesulfonamide and

4-[3-(4-Chloro-phenyl)-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidin-4-yl]-benzenesulfonamide.

4. A compound of formula (Ic)

their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their solvates, their pharmaceutically acceptable salts and their pharmaceutically acceptable compositions, wherein X and Y may be same or different and independently represent oxygen, sulfur or NR, wherein R represents hydrogen, hydroxyl, acyl, alkyl, alkoxy, aryl, amino, hydroxylamino, alkylamino, arylamino, acylamino, alkoxyamino group; the rings represented by A and B are selected from aryl or heteroaryl; R 1 and R 3 may be same or different and independently represent SR 7 , wherein R 7 represents alkyl or aryl, or S(O) p R 8 , wherein R 8 represents alkyl, amino or aryl group and p represents an integer of 1 or 2; R 2 and R 4 may be same or different and independently represent hydrogen, halogen, hydroxyl, nitro, cyano, azido, nitroso, amino, formyl, alkyl, haloalkyl, acyl, alkoxy, monoalkylamino, dialkylamino, acylamino, alkoxycarbonyl, alkylsulfonyl, alkylsulfinyl, alkylsulfanyl, sulfamoyl, alkoxyalkyl groups or carboxylic acids or its derivatives; R 5 and R 6 may be same or different and independently represent hydrogen, halogen, hydroxyl, formyl, cyano, nitro, nitroso, amino, alkyl, acyl, monoalkylamino, dialkylamino, arylamino, acylamino, alkoxyalkyl or COR 9 , wherein R 9 represents hydroxyl, amino, halogen, alkoxy, aryloxy, monoalkylamino, dialkylamino, arylamino, groups; m is an integer and is in the range of 0 to 2; n is an integer and is in the range of 0 to 2.

5. A pharmaceutical composition which comprises a compound of formula (I)

as defined in claim 1 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

6. A pharmaceutical composition as claimed in claim 5 , in the form of a tablet, capsule, powder, syrup, solution or suspension.

7. A pharmaceutical composition which comprises a compound as claimed in claim 3 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

8. A pharmaceutical composition as claimed in claim 7 , in the form of a tablet, capsule, powder, syrup, solution or suspension.